Market Newsdesk

LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 128,600 of the Company’s common shares to two new employees on April 1, 2025 (each, a “Grant”).

The Grants were offered as material inducement to the employees’ employment. The grants were approved by the Compensation Committee of the Company’s Board of Directors pursuant to the Company’s Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE’s Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on LinkedIn.

ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “would”, “expect”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “future”, “continue”, or “appear” or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the expected cash runway into mid-2026 the Company’s ability to grow ZYNLONTA^® revenue in the United States; the ability of our partners to commercialize ZYNLONTA^® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA^® in foreign jurisdictions; the timing and results of the Company’s or its partners’ research and development projects or clinical trials including LOTIS 5 and 7, ADCT 602 as well as early research in certain solid tumors with different targets, linkers and payloads; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company’s products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company’s indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company’s activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and in the Company’s other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:

Investors

Marcy Graham

ADC Therapeutics
[email protected]
+1 650-667-6450

Media

Nicole Riley

ADC Therapeutics
[email protected]
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-makes-grants-to-new-employees-under-inducement-plan-302414722.html

SOURCE ADC Therapeutics SA

SAN DIEGO
, April 1, 2025 /PRNewswire/ — Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively.

Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer. Inhibrx and the new company have entered into an exclusive license agreement for the rights to certain technologies no longer being pursued by Inhibrx. The agreement includes an upfront payment upon completion of the initial funding of Dr. Eckelman’s new company and other future development milestones.

“I would like to express my deep gratitude to Brendan for his extraordinary contributions to Inhibrx over the last 15 years,” said Mark Lappe, CEO of Inhibrx. “Brendan has had a profound impact on Inhibrx and we expect he will lead this next endeavor to the same success.”

“I am immensely proud of the achievements and groundbreaking innovations we have developed since co-founding Inhibrx in 2010. As I announce my departure, it is a bittersweet moment.,” says Dr. Eckelman. “I have the utmost confidence in the team and the culture of innovation I’m leaving behind and look forward to continuing to support Inhibrx in my capacity as a shareholder.”

Dr. Carlos Bais, the Company’s current Executive Vice President of Translational Sciences, will be appointed to CSO following Dr. Eckelman’s departure.

Additionally, the Company also announced the promotion of David Matly to President in addition to his existing roles as Chief Commercial and Business Development Officer. In David’s new role as President, he will continue to lead the commercial and business development functions as well as oversee clinical development and operations, R&D, technical operations and regulatory affairs. Notably, David played a key leadership role in Inhibrx, Inc.’s asset sale of INBRX-101 to Sanofi for up to $2.2B in 2024.

“We believe we are exceptionally well-positioned for continued success as Carlos steps into the role of CSO and David into the role of President,” continued Mr. Lappe. “Carlos’s strong scientific background and expertise in late-stage development make him a perfect candidate to assume the CSO role. And David’s cross-functional understanding of successfully delivering best-in-class new therapies, combined with his ambition and commitment to the Company will prove to be pivotal to our future success. Each will play a crucial role as we continue to execute on our clinical programs in an effort to deliver significant impact to patients while maximizing the value to our shareholders.”

About Dr. Bais

Dr. Bais began his career in the biopharmaceutical industry as a research lab head at Genentech and then as a Senior Director and Principal Scientist in the oncology biomarker development department. Later he served as a Director of Translational Medicine for cancer immunotherapy at Medimmune/Astrazeneca, and most recently prior to Inhibrx, as a Senior Director and Principal Scientist in the oncology biomarker development department at Genentech/Roche. Throughout his career, Dr. Bais led impactful research and translational strategies for multiple late-stage programs that resulted in high impact publications and drug approvals in diagnostic-positive patient subpopulations. Some of the drugs Dr. Bais and his team supported included Astrazeneca’s Durvalumab (anti-PD-L1) and Tremelimumab (anti-CTLA-4), and Roche’s Atezoluzimab (anti-PD-L1), Tiragolumab (anti-Tigit), and Bevacizumab (Avastin, anti-VEGF); he also oversaw biomarker support for early-stage drug candidate development, including T-cell engagers and therapies, along with individualized neoantigen cancer vaccines.

About Mr. Matly

Mr. Matly joined Inhibrx, Inc. in October 2021 from Novartis, where he most recently served as the global Vice President of the MDS/AML franchise. In this role, he was responsible for the launch preparation of their flagship program and building the MDS/AML portfolio, including the evaluation of in-licensing and M&A opportunities. Prior to this role, Mr. Matly was Novartis Oncology’s global commercial lead of the sickle cell disease therapeutic area, leading the launch of ADAKVEO, and also serving as the global commercial lead of PROMACTA/REVOLADE. Prior to Novartis, Mr. Matly was the VP of Business Development at Chrono Therapeutics, a private venture capital-backed company. Mr. Matly began his career at Eli Lilly, holding several positions of increasing responsibility in sales and marketing, most notably leading the US launch of CYRAMZA in metastatic lung cancer.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences’ current clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. Both programs have key data readouts expected in 2025. For more information, please visit www.inhibrx.com.

Forward-Looking Statements

Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: the future success of the Company, future clinical development of Inhibrx’s therapeutic candidates and which technologies it may pursue, including statements regarding the timing of future data readouts, and evaluations and judgments regarding Inhibrx’s position and success. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx’s business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; any adverse impacts from the transition in senior leadership roles; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its ability to raise funds needed to satisfy its capital requirements, which may depend on financial, economic and market conditions and other factors, over which it may have no or limited control; developments relating to its competitors and industry; and other risks described from time to time in the “Risk Factors” section of its filings with the U.S. Securities and Exchange Commission, including those described in its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, and supplemented from time to time by its Current Reports on Form 8-K as filed from time to time. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor and Media Contact:
Kelly Deck, CFO
[email protected]
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-biosciences-announces-departure-of-cso-and-appointments-of-new-cso-and-president-302416729.html

SOURCE Inhibrx Biosciences, Inc.

DALLAS
, April 1, 2025 /PRNewswire/ — Digital Realty (NYSE: DLR), the largest global provider of cloud- and carrier-neutral data center, colocation, and interconnection solutions, announced today that it will release financial results for the first quarter of 2025 after the market closes on Thursday, April 24, 2025. The company will host a conference call to discuss these results at 5:00 p.m. ET / 4:00 p.m. CT on Thursday, April 24, 2025. 

To participate in the live call, investors are invited to dial +1 (888) 317-6003 (for domestic callers) or +1 (412) 317-6061 (for international callers) and reference the conference ID #9420618 at least five minutes prior to start time. A live webcast of the call will be available on the Investors section of Digital Realty’s website at https://investor.digitalrealty.com. 

Telephone and webcast replays will be available one hour after the call until May 24, 2025. The telephone replay may be accessed by dialing +1 (877) 344-7529 (for domestic callers) or +1 (412) 317-0088 (for international callers) and using the conference ID #2558953. The webcast replay may be accessed on Digital Realty’s website. 

About Digital Realty
Digital Realty brings companies and data together by delivering the full spectrum of data center, colocation and interconnection solutions. PlatformDIGITAL®, the company’s global data center platform, provides customers with a secure data meeting place and a proven Pervasive Datacenter Architecture (PDx ®) solution methodology for powering innovation and efficiently managing Data Gravity challenges. Digital Realty gives its customers access to the connected data communities that matter to them with a global data center footprint of 300+ facilities in 50+ metros across 25+ countries on six continents. To learn more about Digital Realty, please visit digitalrealty.com or follow us on LinkedIn and X.

For Additional Information

Investor Relations

Jordan Sadler / Jim Huseby
Digital Realty
+1 415 275 5344
[email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/digital-realty-schedules-first-quarter-2025-earnings-release-and-conference-call-302417412.html

SOURCE Digital Realty Trust

NEWTON, Mass.
, April 1, 2025 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of March 31, 2025 (the “Grant Date”) pursuant to the Company’s 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a “change in control event,” the employee’s employment is terminated for “good reason” by the employee or terminated without “cause” by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm’s lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302412200.html

SOURCE Karyopharm Therapeutics Inc.

Facility materially reduces interest rate with added flexibility

TUCSON, Ariz.
, April 1, 2025 /PRNewswire/ — AudioEye, Inc. (Nasdaq: AEYE) (“AudioEye” or the “Company”), the industry-leading digital accessibility company, today announced a new $20 million loan facility with Bridge Bank, a division of Western Alliance Bank, Member FDIC (NYSE: WAL), a financial institution with over $80 billion of assets.

The new facility comprises a $12 million term loan, a $3 million revolver, and a $5 million delayed draw term loan for potential “tuck in” acquisitions. The rate of the new facility represents a significant reduction on the existing facility. The new facility will mature on the fifth anniversary of the facility’s closing. The initial $12 million term loan will fully repay AudioEye’s existing term loan, dated November 30, 2023, and further strengthen the Company’s cash position. The revolver and delayed draw term loan feature the same interest rate as the term loan and remain available for further strategic opportunities.

“Over the last few quarters, our operating leverage has become clear with material improvements in our credit profile. We expect further improvements in operating leverage this year, with adjusted EBITDA expected to increase by 42% year-over-year using the mid-point of the guidance previously issued. The new facility features a reduction of interest rate of approximately 6.5% and added flexibility for strategic opportunities,” said Kelly Georgevich, CFO of AudioEye. “We look forward to partnering with Bridge Bank and Western Alliance Bank through our next growth phase.”

Francesco Corradino, Director, Technology & Innovation Banking at Bridge Bank, added, “Bridge Bank is proud to be AudioEye’s banking partner as they continue in their mission of making the digital world more accessible for everyone. We believe in their market opportunity and unique approach to solving for accessibility. This loan reflects our team’s ongoing commitment to banking relationships with best-in-class companies like AudioEye.”

Bridge Bank’s Technology & Innovation Banking Group supports technology companies at all stages of their life cycles with customized banking services and credit solutions to help them navigate rapidly changing environments.

About AudioEye

AudioEye exists to ensure the digital future we build is accessible. The gold standard for digital accessibility, AudioEye’s comprehensive solution combines industry-leading AI automation technology with expert fixes informed by the disability community. This powerful combination delivers industry-leading protection, ensuring businesses of all sizes – including over 127,000 customers like Samsung, Calvin Klein, and Samsonite – meet and exceed compliance standards. With 24 US patents, AudioEye’s solution includes 24/7 accessibility monitoring, automated WCAG issue testing and fixes, expert testing, developer tools, and legal protection, empowering organizations to confidently create accessible digital experiences for all.

About Bridge Bank
Bridge Bank, a division of Western Alliance Bank, Member FDIC, delivers relationship banking that puts clients at the center of everything. Founded in 2001 in Silicon Valley, Bridge Bank offers a full spectrum of tailored commercial banking solutions with specialized expertise focused on life sciences and technology and innovation companies at every stage in their life cycle, from startup to IPO and beyond. With offices in major tech hubs across the country, Bridge Bank delivers the reach, resources, and market expertise that make a difference for its clients. Bridge Bank also serves the private equity and venture capital communities by providing banking solutions for portfolio companies and funds, plus banking solutions for small to mid-size businesses in the Bay Area. Bridge Bank is part of Western Alliance Bancorporation, which has more than $80 billion in assets. Major accolades include being ranked as a top U.S. bank in 2024 by American Banker and Bank Director. For more information, visit Bridge Bank.

Forward-Looking Statements


Any statements in this press release about AudioEye’s expectations, beliefs, plans, objectives, prospects, financial condition, assumptions or future events or performance are not historical facts and are “forward-looking statements” as that term is defined under the federal securities laws. Forward-looking statements are often, but not always, made through the use of words or phrases such as “believe”, “anticipate”, “should”, “confident”, “intend”, “plan”, “will”, “expects”, “estimates”, “projects”, “positioned”, “strategy”, “outlook” and similar words. You should read the statements that contain these types of words carefully. Such forward-looking statements contained herein include, but are not limited to, statements regarding future cash flows of the Company, acquisition opportunities, long-term growth prospects, and our adjusted EBITDA guidance. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from what is expressed or implied in such forward-looking statements, including the variability of AudioEye’s revenue and financial performance; sales channels and offerings; product development and technological changes; the acceptance of AudioEye’s products in the marketplace; the effectiveness of our integration efforts; competition; inherent uncertainties and costs associated with litigation; and general economic conditions. These and other risks are described more fully in AudioEye’s filings with the Securities and Exchange Commission. There may be events in the future that AudioEye is not able to predict accurately or over which AudioEye has no control. Forward-looking statements reflect management’s view as of the date of this press release, and AudioEye urges you not to place undue reliance on these forward-looking statements. AudioEye does not undertake any obligation to update such forward-looking statements to reflect events or uncertainties after the date hereof.

Media Contact

Sierra Thomas

AudioEye PR
[email protected]

Investor Contact

Tom Colton

Gateway Group, Inc.
[email protected]
949-574-3860

View original content to download multimedia:https://www.prnewswire.com/news-releases/audioeye-announces-new-commercial-bank-loan-facility-302417355.html

SOURCE AudioEye, Inc.